Emcure Pharmaceuticals has been assigned an Environmental, Social, and Governance (ESG) rating of 21 for the financial year 2024-25. This rating was independently and voluntarily provided by NSE Sustainability Ratings & Analytics Limited, a SEBI registered ESG Rating Provider. The rating is based on publicly available information.
The company received notification of this rating via email on 7 May 2026. The ESG rating reflects Emcure‘s commitment to sustainable practices and transparency in its operations.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).